PT-141 for Libido: What the Evidence Shows
What human and animal studies show about PT-141 for libido, how strong that evidence is, and what is still unproven.
- Strongest evidence
- Human RCT
- Human studies
- 8
- PubMed records, our ledger
- Animal studies
- 1
- PubMed records, our ledger
- Studies we summarised
- 9
- with an outcome for libido
Evidence for libido
Each row is an outcome related to libido from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Desire and distress across subgroups | Benefit on desire and distress was seen across age, weight and BMI subgroups. | Human RCTn = 1202 | Journal of women's health 2022, PMID 35230162 |
| Patient-reported experience | Exit surveys and interviews: bremelanotide users described more desire, arousal and better sexual activity quality. | Human RCTn = 242 | Journal of women's health 2021, PMID 33538638 |
| Sexual desire (FSFI-desire domain) | Desire domain score rose more than placebo: 0.30 (study 301), 0.42 (study 302), 0.35 integrated, all P<.001. | Human RCTn = 1267 | Obstetrics and gynecology 2019, PMID 31599840 |
| Distress related to low desire | Distress fell more than placebo: -0.37, -0.29 and -0.33 integrated. | Human RCTn = 1267 | Obstetrics and gynecology 2019, PMID 31599840 |
| Responder rates | At 1.75 mg, responder rates beat placebo on all 7 endpoints (P ≤ .03). | Human RCT | The journal of sexual medicine 2019, PMID 31277966 |
| Satisfying sexual events | +0.7 versus +0.2 satisfying sexual events per month (p = 0.0180). | Human RCTn = 327 | Women's health 2016, PMID 27181790 |
| Positive clinical response in sildenafil non-responders | 51 (33.5%) of the bremelanotide group had positive clinical results versus 13 (8.5%) on placebo (p = 0.03). | Human RCTn = 342 | The Journal of urology 2008, PMID 18206919 |
| Sexual desire | More women reported moderate or high desire after bremelanotide than placebo (P = 0.0114). | Human RCTn = 18 | The journal of sexual medicine 2006, PMID 16839319 |
| Vaginal vasocongestion | No significant change in vaginal vasocongestion versus placebo. | Human RCTn = 18 | The journal of sexual medicine 2006, PMID 16839319 |
| Erectile response (RigiScan) | Erectile response was statistically significant versus placebo at both 4 mg and 6 mg in men with inadequate response to Viagra. | Human RCT | International journal of impotence research 2004, PMID 14999221 |
| Erectile response (RigiScan) | Erectile response beat placebo at doses above 7 mg; first erection began in about 30 minutes. | Human RCT | International journal of impotence research 2004, PMID 14963471 |
PubMed records for PT-141 and libido: 8 human, 1 animal (search counts, not studies we reviewed). Grades follow our evidence scale.
How strong is it?
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
Other peptides people research for libido
Common questions
Does PT-141 help with libido?
The strongest study we summarise for libido is human rct evidence, across 9 studies with an outcome for libido. A trial result is not an approval; see the legal status.
Is PT-141 approved for libido?
PT-141 is FDA approved for HSDD (Vyleesi). Which conditions that approval covers is set by the label; use for anything else is off-label.
More on PT-141
DosageDoses used in published studies, with the source for each.CalculatorVial, water and dose to syringe units.Side effectsWhat labels and studies report, and what is unknown.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.Legal statusFDA, compounding and WADA status with dates.
Sources
- 1Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.Journal of women's health (2002) · 2022PMID 35230162Accessed 2 Oct 2026
- 2The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results.Journal of women's health (2002) · 2021PMID 33538638Accessed 2 Oct 2026
- 3Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.Obstetrics and gynecology · 2019PMID 31599840Accessed 2 Oct 2026
- 4Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.The journal of sexual medicine · 2019PMID 31277966Accessed 2 Oct 2026
- 5Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.Women's health (London, England) · 2016PMID 27181790Accessed 2 Oct 2026
- 6Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study.The Journal of urology · 2008PMID 18206919Accessed 2 Oct 2026
- 7An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.The journal of sexual medicine · 2006PMID 16839319Accessed 2 Oct 2026
- 8Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra.International journal of impotence research · 2004PMID 14999221Accessed 2 Oct 2026
- 9Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction.International journal of impotence research · 2004PMID 14963471Accessed 2 Oct 2026
Found an error? Report a correction.